Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Hapten licenses HPT-721 to prevent poison ivy dermatitis

Hapten Sciences Inc. of Memphis, Tenn., has licensed a compound developed by ElSohly Laboratories Inc. and University of Mississippi pharmaceutical researchers to prevent reactions to poison ivy, oak and sumac.

27 Mar 2012

FDA issues Complete Response letter to MAP's NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

27 Mar 2012

USANA Health Sciences expands into French and Belgium markets

USANA Health Sciences, Inc., a global nutritional supplements company, today announced the official opening of its France and Belgium markets. Bringing the company's international expansion to 18 countries worldwide, USANA's newest office will reside on the Champs-Elysees in Paris and will initially offer seven nutritional supplements and eight skin-care products.

26 Mar 2012

BioLife fourth quarter total revenue increases 41% to $809,564

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced record revenue for the fourth quarter and full year 2011, and for the first time, provided initial guidance on management's outlook for the full year 2012.

26 Mar 2012

BiO2 Medical completes $13.7M Series B round of funding

BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently completed its $13.7M Series B round of funding, which included the conversion of a $1M State of Texas Emerging Technology Fund (ETF) award.

26 Mar 2012

Africa must develop its own pharmaceutical pipeline through creation of policy frameworks

"To break free of its dependence on donor money and supplies from India, Africa must develop its own pharmaceutical pipeline by creating policy frameworks that encourage a fledgling drug industry," journalist Priya Shetty argues in this SciDev.Net opinion piece.

23 Mar 2012

China SFDA approves Taibang's clinical trials for human fibrinogen

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd., recently received approval from the China State Food and Drug Administration to begin clinical trials for its human fibrinogen to be used to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency.

23 Mar 2012

Ensuring clean water for food, health requires 'collective action'

"As we mark World Water Day, the alarming statistics underlying water scarcity are worth repeating. Worldwide 2.7 billion people are currently affected by water shortages," Manish Bapna, acting president of the World Resources Institute (WRI), and Betsy Otto, director of WRI's Aqueduct Project, write in a Forbes opinion piece, noting that population growth, increasing food demand, and climate change threaten access to water.

23 Mar 2012

As need for nurses increases, more men enter the profession

As the country faces a shortage of doctors, nurses may help fill the void and the government and industry are working to make sure there are enough of these professionals.

23 Mar 2012

FMBFarma granted exclusive rights to market Ampio's Zertane for PE in Brazil

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, and FBM Industria Farmaceutica Ltda, a member of the HOSPFAR Group that manufactures, imports and distributes pharmaceuticals in Brazil, today announced a license and distribution agreement providing FMBFarma exclusive rights to market Zertane in Brazil for the treatment of premature ejaculation.

22 Mar 2012

First Edition: March 22, 2012

Today's headlines include examinations of the health law as it approaches its two-year anniversary and its review by the Supreme Court, as well as reports about what's next for the Ryan budget plan.

22 Mar 2012

IQMS releases new version of ERP software, EnterpriseIQ

IQMS, a manufacturing ERP software developer with an ongoing, proactive commitment to its product and relationships, today announced the release of a new version of its manufacturing ERP software, EnterpriseIQ. Featuring more than 1,000 enhancements and reports across all aspects of the system, IQMS' newest release again demonstrates its commitment to the product and its clients.

21 Mar 2012

ISCO fourth quarter revenue increases 110% to $1.1 million

International Stem Cell Corporation today announced year-end financial results for the year ended December 31, 2011.

21 Mar 2012

IGI fourth quarter total revenues increase 21% to $2.1M

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011.

21 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

Tobii completes USD $21 million funding round

Tobii Technology, the global leader in eye tracking and gaze interaction, announced today that it has closed a USD $21M funding round. New investor Intel Capital joins existing investors Amadeus Capital, Investor Growth Capital and Northzone Ventures.

20 Mar 2012

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine

PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.

19 Mar 2012

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.

17 Mar 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012